Abstract
Background: The management of type 1 diabetes (T1D includes aiming to achieve optimal glucose management to avoid complications, but this remains a challenge.) Aim: To identify factors related to optimal glycemic management (A1c Methods: The analysis included 8,062 T1D adults (18 - 65 years) in the T1DX-QI database for whom electronic medical record data were available, with at least one completed clinic encounter July 2017 - February 2020. Results: In this population (age range 18 to 65 years), 20% (N=1,609) of T1D adults had optimal glycemic management (A1c Conclusion: These real-world data highlight racial disparities, the difficulty achieving A1c Disclosure N. Rioles: None. S. Polsky: Advisory Panel; Self; Medtronic, Consultant; Self; National Institutes of Health, Research Support; Self; Dexcom, Inc., Eli Lilly and Company, JDRF, Medtronic, National Institute of Diabetes and Digestive and Kidney Diseases, Sanofi US, T1D Exchange. O. Ebekozien: None. N. Noor: Research Support; Self; Dexcom, Inc. F. Vendrame: None. M. Basina: None. R. S. Weinstock: Research Support; Self; Boehringer Ingelheim International GmbH, Diasome Pharmaceuticals, Inc., Eli Lilly and Company, Insulet Corporation, Kowa Research Institute, Inc., Medtronic, Tolerion, Inc. Funding The Leona M. and Harry B. Helmsley Charitable Trust
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
